Bad news for Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News, Analysts, Financials... Read More
The stock has been on a roll, but Paradigm Capital analyst Scott McAuley thinks there is still money... Read More
Following the company’s Q2, 2024 interim results, Echelon Capital Markets analyst Stefan Quenn... Read More
After first quarter results that were largely in-line with his expectations, Echelon Capital Markets... Read More
Investors searching for a high risk-tolerant stock in the biotech field should be thinking about Ant... Read More
Clinical-stage biotech company Antibe Therapeutics (Antibe Therapeutics Stock Quote, Charts, News, A... Read More
Canadian biotech company Antibe Therapeutics (Antibe Therapeutics Stock Quote, Charts, News, Analyst... Read More
It seems fair to say that biotech hasn’t been the hottest of fields for much of this year. Money c... Read More
Stefan Quenneville of Echelon Capital Markets has lowered his expectations for Antibe Therapeutics (... Read More
A safety issue with its lead drug has chopped a big hole in the share price for Canadian pharma comp... Read More
Keep your eyes on the prize, that’s the message for investors looking at Antibe Therapeutics (Anti... Read More
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had a turbulent coup... Read More
Investment bankers Paradigm Capital launched coverage on Wednesday of drug developer Antibe Therapeu... Read More
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has performed well both ... Read More
Canadian Life Sciences stocks have been on a roller coaster ride so far in 2019. The sector, which i... Read More
Echelon Wealth Partners analyst Douglas Loe is holding steady on his investment thesis for clinical ... Read More
Echelon Wealth Partners analyst Douglas Loe is staying bullish on clinical stage drug developer Anti... Read More
In an update to clients Wednesday, Echelon Wealth Partners analyst Douglas Loe remains bullish on cl... Read More